EPHA7
EPHA7 (Ephrin type-A receptor 7) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer, Neuroendocrine tumours, Colorectal cancer and 2 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells. The signalling pathway downstream of the receptor is referred to as forward signalling while the signalling pathway downstream of the ephrin ligand is referred to as reverse signalling. Among GPI-anchored ephrin-A ligands, EFNA5 is a cognate/functional ligand for EPHA7 and their interaction regulates brain development modulating cell-cell adhesion and repulsion. Has a repellent activity on axons and is for instance involved in the guidance of corticothalamic axons and in the proper topographic mapping of retinal axons to the colliculus. May also regulate brain development through a caspase(CASP3)-dependent proapoptotic activity. Forward signalling may result in activation of components of the ERK signalling pathway including MAP2K1, MAP2K2, MAPK1 and MAPK3 which are phosphorylated upon activation of EPHA7. Location: Cell membrane (UniProt). Locus 6q16.1 (HGNC).
- Thyroid cancer: Open Targets association 0.62 with thyroid cancer (MONDO_0002108)
- Neuroendocrine tumours: Open Targets association 0.61 with neuroendocrine neoplasm (MONDO_0019496)
- Colorectal cancer: IntOGen driver in 1 cohort (COADREAD)
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Non-small-cell lung cancer: IntOGen driver in 1 cohort (LUAD)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"EPHA7" OR ABSTRACT:"EPHA7" OR TITLE:"EPH receptor A7" OR ABSTRACT:"EPH receptor A7" OR TITLE:"Ephrin type-A receptor 7" OR ABSTRACT:"Ephrin type-A receptor 7" OR TITLE:"Hek11" OR ABSTRACT:"Hek11") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EPHA7, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/epha7.json. Licence CC BY-NC 4.0.